Plain-English translation of NCT04739722 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers studied a new stool-based screening test called ColoSense that was designed to detect colorectal cancer and precancerous polyps without the need for a colonoscopy. The test analyzed stool samples for genetic material (RNA) and combined those results with a standard immunochemical test and smoking history. This trial compared how well the ColoSense test performed against the results from colonoscopy, which is considered the gold standard for detecting these conditions.
Colorectal cancer is a major health concern, but many people avoid screening because colonoscopy can feel invasive or uncomfortable. Researchers wanted to develop a simpler, less invasive stool-based test that could reliably detect cancer and precancerous polyps earlier, when treatment is most effective.
Participants collected a stool sample at home and brought it to their scheduled colonoscopy appointment. Before the colonoscopy, they completed the ColoSense test, which analyzed their stool sample for genetic markers and combined those findings with a standard immunochemical test and information about their smoking status. Doctors then compared the test results to what they found during the colonoscopy to see how accurately the new stool test could detect cancer and precancerous polyps.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States